Critical Role of Identification of the Second Gland During Unilateral Parathyroid Surgery

A Prospective Review of 119 Patients With Concordant Localization

Nancy L. Cho, MD; Atul A. Gawande, MD, MPH; Eric G. Sheu, MD, DPhil; Francis D. Moore Jr, MD; Daniel T. Ruan, MD

**Hypothesis:** We aimed to validate the effectiveness of a protocol for primary hyperparathyroidism in which intraoperative parathyroid hormone measurement (IOPTH) was not routinely used during minimally invasive parathyroidectomy for patients with dual localization by technetium Tc 99m sestamibi (MIBI) and ultrasonography and hypothesized that our rate of surgical failure would be less than 3% for patients with concordant localization.

**Design:** Prospective cohort study.

**Setting:** Brigham and Women’s Hospital, Boston, Massachusetts.

**Patients:** One hundred nineteen patients with primary hyperparathyroidism and dual localization.

**Main Outcome Measures:** Incidence of surgical cure following minimally invasive parathyroidectomy (MIP) without the use of IOPTH for patients with dual localization.

**Results:** A total of 324 patients with primary hyperparathyroidism underwent parathyroid exploration between October 1, 2005, and September 30, 2009. In 136 patients (42.0%), imaging was concordant by MIBI and ultrasonography, and 119 patients were scheduled for MIP. Our protocol for MIP without IOPTH was successful in 115 patients (97%), with 13 cases converted to bilateral exploration based on intraoperative suspicion of multiglandular disease. Eight of 13 conversions (62%) revealed multiglandular disease that was undetected on imaging, 6 of which were apparent from examination of the ipsilateral second parathyroid gland. Four of 136 patients (3%) had persistent postoperative hypercalcemia necessitating reoperation, and all 4 had an adjacent but unseen second adenoma. There was no significant difference in the surgical cure rate following MIP without IOPTH for this prospective study vs a previously published retrospective analysis by our group (97% vs 98%, P = .47).

**Conclusions:** Focused parathyroid gland exploration without IOPTH can be successfully performed in a select group of patients with dual localization by MIBI and ultrasonography. However, identification of the second ipsilateral gland may be critical to ruling out undetected multiglandular disease.

Arch Surg. 2011;146(5):512-516

A PPROXIMATELY 100 000 NEW cases of primary hyperparathyroidism (PHPT) are diagnosed in the United States each year.¹ Of these cases, most are caused by a single parathyroid adenoma (80%-87%), followed by 4-gland hyperplasia (10%-15%), multiple adenomas (2%-5%), and carcinoma (<1%). Recent advances in imaging modalities have enabled surgeons to offer a minimally invasive, or unilateral, approach for the surgical treatment of PHPT to patients with single-gland disease. A recent survey among members of the American Association of Endocrine Surgeons demonstrated a growing trend in the number of minimally invasive parathyroidectomies (MIPs) performed in 2008 (up to 92%).² Compared with traditional bilateral neck exploration, MIP allows surgeons to resect a single adenoma through a small incision without dissection on the contralateral side. As such, MIP offers patients the advantage of a smaller incision, decreased operative time, and fewer complications, such as nerve injury or permanent hypoparathyroidism.³ In addition, many surgeons use intraoperative parathyroid hormone measurement (IOPTH) as an adjunct to MIP. However, the role of IOPTH in MIP remains controversial.

See Invited Critique at end of article

Our group previously published a retrospective study⁴ investigating the role of IOPTH during MIP in cases of PHPT with concurrent localization by technetium Tc 99m sestamibi (MIBI) and ultrasonography (US). Results showed that the surgical failure rate in patients with concom-
tients with dual localization. Additional studies\(^5\)\(^-\)\(^8\) have
does not significantly increase the success of MIP for pa-
gest suggests a surgical success rate of 95% to 97.5% without
IOPTH vs 97% to 99% with IOPTH.\(^9\)\(^-\)\(^13\)

Figure 1. Flowchart of the study design.

Under a protocol approved by the institutional review board of
the Brigham and Women's Hospital, Boston, Massachusetts, we
collected clinical data on all patients with PHPT undergoing US,
sestamibi imaging, and parathyroidectomy at the hospital be-
tween October 1, 2005, and September 30, 2009. Patients with
recurrent disease were excluded. Recorded data included the site
of localization (if any) in each of the 2 imaging studies, the find-
ings at surgical exploration, and postoperative calcium and para-
thyroid hormone measurements. We implemented our protocol
for all patients with PHPT and concordant localization who qual-
ified for MIP. Our outcome measurement was the incidence of sur-
gical cure following MIP without the use of IOPTH. A represen-
tative study design is shown in Figure 1.

Imaging by MIBI was performed by administering 16 to 20
milliCurie (mCi) of MIBI intravenously and by obtaining early
and delayed planar images (at 15 minutes and at 2-3 hours).
Ultrasonography was performed primarily by dedicated radi-
ologists using color and power Doppler imaging. The radiolo-
gists performing either study were not blind to prior imaging
results.

If findings for either study were at least suggestive of a pos-
sible site for a parathyroid adenoma, we regarded the study as
positive for localization. We considered MIBI and US imaging
concordant if they both localized a single adenoma on the same
side of a patient's neck. They were discordant if one localized
an adenoma and the other did not or if they localized disease
on opposite sides of the neck. Patients with discordant local-
ization who were scheduled for bilateral neck exploration be-
cause of a history of renal failure, prior lithium use, or sub-
stantially enlarged glands on preoperative US (>2.5 cm) were
excluded from the concordant group.

If MIBI and US imaging results were discordant, we per-
formed MIP without IOPTH focused on that site with limited
incision and without contralateral exploration. For all pa-
tients scheduled for MIP, we also examined the ipsilateral
normal parathyroid gland to avoid missing undetected multiglan-
dular disease. Cases were converted to bilateral neck exploration
based on criteria for intraoperative suspicion of multiglandu-
lar disease, including the finding of an enlarged gland exceed-
ing 2 cm during surgery, obscure anatomy, or an abnormal-
appearing second ipsilateral gland.

Calcium and parathyroid hormone measurements were ob-
tained at postoperative follow-up visits, generally 2 to 4 weeks
following surgery, and we recorded whether these confirmed
the resolution of hypercalcemia. We routinely repeat calcium level
measurements approximately 3 and 6 months following surgery,
and these levels were documented if obtained. If the patient re-
mained persistently hypercalcemic with an inappropriately el-
evated parathyroid hormone level after parathyroidectomy, de-
spite correct localization, this was considered a surgical failure.

The rates of surgical failure between the previous retrospec-
tive study and this study were compared using the 2-tailed Fisher
exact test. \(P<.05\) was considered statistically significant.

RESULTS

A total of 324 parathyroid gland surgical explorations for
PHPT were performed at the Brigham and Women's Hospital
(Figure 2). In 188 patients, imaging was discordant,
negative, or not obtained, or only a single localization
study was performed (Table 1). In 136 patients (42.0%),
MIBI and US imaging identified the same single site of
disease (imaging was concordant). Seventeen patients
were not offered MIP because of exclusion criteria, in-
cluding renal failure, prior lithium use, or enlarged glands
exceeding 2.5 cm on US, which are predisposing factors
for multiglandular disease. One hundred nineteen pa-
tients were then scheduled for MIP without IOPTH, and

Figure 2. Summary of results. Our study protocol was implemented for all
patients with primary hyperparathyroidism and concordant localization by
technetium Tc 99m sestamibi (MIBI) and ultrasonography (US) undergoing
minimally invasive parathyroidectomy without intraoperative parathyroid
hormone level measurement. \(\text{T}^\text{Ca}\) indicates elevated calcium level.
our protocol was successful in 115 patients, for a 96.6% surgical cure rate. Four patients had persistent postoperative hypercalcemia necessitating reoperation.

As part of our new protocol, we also examined the ipsilateral second parathyroid gland among all patients scheduled for MIP in an effort to detect multiglandular disease. Among 119 patients originally scheduled for MIP, 13 cases were converted to bilateral exploration based on criteria for intraoperative suspicion of multiglandular disease, including an enlarged gland, obscure anatomy, or an abnormal-appearing second ipsilateral gland. Eight of 13 conversions ultimately revealed multiglandular disease that was undetected on preoperative imaging. Six of these cases were apparent from examination of the ipsilateral second parathyroid gland alone. A summary of the characteristics among patients undergoing conversion to bilateral neck exploration is given in Table 2. Twelve of 13 patients who underwent conversion to bilateral neck exploration were cured following their surgery. Patient 6 had persistent postoperative hypercalcemia, and reoperation demonstrated an intrathymic parathyroid adenoma, suggesting the presence of a supernumerary gland or incomplete resection of a lower parathyroid adenoma during the original operation.

Finally, of 4 surgical failures, all 4 had a near adjacent but unseen second adenoma on reoperation, suggesting that visualization of the second ipsilateral gland was incorrectly identified during the original surgery. Final pathology reports confirmed the presence of dual ipsilateral adenomas, and all patients experienced resolution of their hypercalcemia following reoperation. There was no significant difference in the surgical cure rate following MIP without IOPTH for this prospective study compared with our previously published retrospective analysis (97% vs 98%, P = .47).4

Minimally invasive parathyroidectomy offers attractive advantages over conventional bilateral neck exploration, including shorter operative time, improved cosmesis, decreased hospitalization, less postoperative recovery time, and reduced morbidity from recurrent laryngeal nerve injury and hypoparathyroidism.1 In addition, both operations have similar outcomes in terms of durable cure.12,13 However, the role of IOPTH during MIP in patients with concordant localization remains controver-

### Table 1. Imaging Among Patients With Primary Hyperparathyroidism

<table>
<thead>
<tr>
<th>Imaging</th>
<th>Patients, No. (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>MIBI and US positive for same site,</td>
<td></td>
</tr>
<tr>
<td>concordant</td>
<td>136 (42.0)</td>
</tr>
<tr>
<td>MIBI and US discordant</td>
<td>96 (29.6)</td>
</tr>
<tr>
<td>MIBI and US negative, no localization</td>
<td>38 (11.7)</td>
</tr>
<tr>
<td>Only 1 mode of imaging, MIBI or US, used</td>
<td>32 (10.0)</td>
</tr>
<tr>
<td>No imaging obtained</td>
<td>22 (6.8)</td>
</tr>
<tr>
<td>Total</td>
<td>324 (100.0)</td>
</tr>
</tbody>
</table>

Abbreviations: MIBI, technetium Tc 99m sestamibi; US, ultrasonography.
neither beneficial nor cost-effective for most patients having PHPT with concordant localization. The question remains: in which patients with dual localization is IOPTH warranted?

Siperstein et al19 published the largest study to date investigating the prevalence of undetected multiglandular disease among patients who were candidates for MIP. They reported unsuspected multiglandular disease in 20% of their patient population with concordant localization by MIBI and US, which was identified on bilateral neck exploration. They also found that the use of IOPTH during these cases decreased the rate of undetected multiglandular disease to only 16%. However, it is important to note that controversy exists about the definition of multiglandular disease, in which some surgeons base their criteria on gland size or histopathologic findings, whereas others argue that neither factor correlates with secretory activity. As demonstrated by our data, identification of an abnormal second gland revealed the presence of double adenomas or multiglandular disease in 6 patients, despite dual localization. In this situation, IOPTH may have a useful role in guiding the appropriate excision of additional abnormal glands that are inadvertently discovered during surgery. Overall, we support the use of IOPTH in patients with PHPT who have dual localization and ambiguous or unexpected operative findings, all of which further supports the importance of correctly identifying the ipsilateral second gland.

As a result of our study, we concur with the prior conclusions of our group that IOPTH during unilateral parathyroid exploration provides no significant benefit for patients with dual localization uncovered by MIBI and US. However, we found that identification of the second ipsilateral gland has a critical role in ruling out undetected multiglandular disease when IOPTH is not used. Because our surgical failures were due to missed adjacent adenomas, despite intraoperative examination of the ipsilateral parathyroid gland, we have adjusted our current protocol to include a frozen section biopsy specimen of the ipsilateral gland to obtain pathological confirmation that the tissue in question is truly parathyroid rather than a lymph node or fatty tissue. We also recognize that, while not a perfect assay, IOPTH can have an important role in patients with equivocal imaging, obscure anatomy, or intraoperative suspicion for multiglandular disease.

Table 2. Characteristics of Patients Undergoing Conversion to Bilateral Neck Exploration

<table>
<thead>
<tr>
<th>Patient No./Sex/Age, y</th>
<th>Calcium Level, mg/dL&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Parathyroid Hormone Level, pg/mL&lt;sup&gt;a&lt;/sup&gt;</th>
<th>Abnormal Second Gland</th>
<th>Pathologic Findings</th>
</tr>
</thead>
<tbody>
<tr>
<td>1/M/72</td>
<td>12.7</td>
<td>480</td>
<td>Yes</td>
<td>Double adenomas</td>
</tr>
<tr>
<td>2/F/53</td>
<td>12.0</td>
<td>284</td>
<td>No; enlarged gland, 2.1 cm</td>
<td>Single adenoma</td>
</tr>
<tr>
<td>3/F/36</td>
<td>12.6</td>
<td>254</td>
<td>No; obscure anatomy</td>
<td>Single adenoma</td>
</tr>
<tr>
<td>4/M/45</td>
<td>11.1</td>
<td>173</td>
<td>No; enlarged gland, 2.3 cm</td>
<td>Single adenoma</td>
</tr>
<tr>
<td>5/F/80</td>
<td>11.1</td>
<td>114</td>
<td>Yes</td>
<td>4-Gland hyperplasia</td>
</tr>
<tr>
<td>6/F/58</td>
<td>11.2</td>
<td>101</td>
<td>Yes</td>
<td>Double adenomas</td>
</tr>
<tr>
<td>7/F/64</td>
<td>11.3</td>
<td>93</td>
<td>Yes</td>
<td>4-Gland hyperplasia</td>
</tr>
<tr>
<td>8/F/63</td>
<td>11.5</td>
<td>108</td>
<td>No; enlarged gland, 1.3 cm (hemorrhagic)</td>
<td>Single adenoma</td>
</tr>
<tr>
<td>9/F/61</td>
<td>10.5</td>
<td>168</td>
<td>No; obscure anatomy</td>
<td>Double adenomas</td>
</tr>
<tr>
<td>10/F/48</td>
<td>12.3</td>
<td>257</td>
<td>No; enlarged gland, 2.4 cm</td>
<td>Single adenoma</td>
</tr>
<tr>
<td>11/F/62</td>
<td>10.8</td>
<td>90</td>
<td>No; obscure anatomy</td>
<td>Double adenomas</td>
</tr>
<tr>
<td>12/F/58</td>
<td>11.0</td>
<td>79</td>
<td>Yes</td>
<td>Double adenomas</td>
</tr>
<tr>
<td>13/F/53</td>
<td>11.3</td>
<td>91</td>
<td>Yes</td>
<td>Double adenomas</td>
</tr>
</tbody>
</table>

SI conversion factors: To convert calcium to millimoles per liter, multiply by 0.25; parathyroid hormone to nanograms per liter, multiply by 1.0.

<sup>a</sup> The calcium and parathyroid values shown are the highest levels recorded for each patient.

REFERENCES


Accepted for Publication: January 3, 2011.

Correspondence: Nancy L. Cho, MD, Department of Surgery, Brigham and Women’s Hospital, 75 Francis St, Boston, MA 02115 (ncho@partners.org).

Author Contributions: The authors had full access to all the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Study concept and design: Cho, Gawande, Moore, and Ruan. Acquisition of data: Cho, Gawande, Sheu, Moore, and Ruan. Analysis and interpretation of data: Cho, Gawande, Sheu, Moore, and Ruan. Drafting of the manuscript: Cho. Critical revision of the manuscript for important intellectual content: Cho, Gawande, Sheu, Moore, and Ruan. Study supervision: Gawande, Moore, and Ruan.

Financial Disclosure: None reported.

Previous Presentations: This study was presented at the 91st Annual Meeting of the New England Surgical Society; October 29, 2010; Saratoga Springs, New York.
How Many Criteria Does It Take to Remove a Single Parathyroid Gland?

The traditional answer is 1 criterion, with 4-gland exploration finding a single adenoma and 3 normal glands. But over the last 20 to 30 years, there has been an increasing impetus to limit surgical exploration, fueled by a series of innovations. These methods identify a single adenoma and to facilitate intraoperative decision making are MIBI imaging, high-resolution US, and rapid IOPTH. MIBI imaging is widely used, but IOPTH is not available at every institution, not all imaging systems are enhanced with single-photon emission computed tomography, and all ultrasonographers are not created equal, nor are all necks created equal in the eyes of the ultrasonographer.

How many items should a surgeon select from this menu to guide successful parathyroidectomy? The study by Cho et al in this issue of Archives of Surgery reports on the experience of the group at Brigham and Women’s Hospital using only concordant MIBI and US imaging and the identification of a normal ipsilateral parathyroid gland to determine that the identified gland is indeed a solitary adenoma. Their group has previously shown that this approach yields a success rate similar to that achieved using IOPTH as an additional adjunct to decision making. The success rate in the present study was 96.6%, which is well within the accepted range quoted in the literature.

Discussions of how few or how many of the available adjuncts a surgeon should use are ongoing and I suspect will continue until other innovations supersede those available. However, I am concerned about accepting a gland imaged before surgery in conjunction with the identification of a normal ipsilateral gland as the sole determinant. Milas et al found a 15.3% incidence of second adenomas, representing 127 of 828 patients studied. What was most concerning is that 82% of these second glands were on the opposite side of the neck. Preoperative imaging and identification of an ipsilateral gland alone do not offer the physiological components to success that a drop in parathyroid hormone level offers.

In the end, each surgeon must choose which adjuncts to use. MIBI imaging is well accepted, and US helps rule out thyroid nodules, which can cause false-positive MIBI imaging results. To me, the physiological reassurance of IOPTH is still valuable. The identification of a normal ipsilateral gland is yet another node in this complex equation, and I think it is a useful addition to the available factors in decision making.

Nicholas P. W. Coe, MD

Author Affiliation: Office of Surgical Education, Baystate Medical Center, Tufts University School of Medicine, Springfield, Massachusetts.

Correspondence: Dr Coe, Office of Surgical Education, Baystate Medical Center, Tufts University School of Medicine, 759 Chestnut St, Springfield, MA 01199 (nicholas.coe@bhs.org).

Financial Disclosure: None reported.